Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Electra Therapeutics, Inc.

NASDAQ: ETRA · Life Sciences · 7 alerts · CIK 2088082

Share price
$8.31Close, Nov 16
Market cap
$522M
Shares outstanding
62.87MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Electra Therapeutics, Inc. filings on SEC EDGAR ↗

4:19 PM ET 10-Q
Financial Results

Electra Therapeutics Q3 2026 Results: Net Loss of $23.9M, Loss Widens

Electra Therapeutics is a clinical-stage biotechnology company focused on SIRP-targeted therapies, specifically its lead candidates ipsoprubart and ELA822. As of November 2026, the company remains pre-revenue with significant operating losses and expects to require substantial additional capital to fund its research and development programs.

Key figure
Net loss $23.9M
4:17 PM ET 8-K
Financial Results

Electra Therapeutics Financial Results

Electra Therapeutics reported third quarter 2026 financial results and provided updates on its SIRP-targeting portfolio, including the advancement of ipsoprubart in a global registrational program for sHLH. The company recently completed a $350 million IPO to fund its clinical pipeline, with several data readouts and enrollment milestones expected throughout 2027.

“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion. Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer.”

Kathy Dong, PharmD, MBA, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.